The differentiation of tumorigenic cancer stem cells into nontumorigenic cancer cells confers
heterogeneity to some cancers beyond that explained by clonal evolution or environmental …

The contribution of tumorigenic stem cells to haematopoietic cancers has been established
for some time, and cells possessing stem-cell properties have been described in several …

Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic
myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most …

Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown
remarkable clinical activity in patients with chronic myelogenous leukaemia (CML) …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …

The amphetamine derivative (±)-3, 4-methylenedioxymethamphetamine (MDMA, ecstasy) is
a popular recreational drug among young people, particularly those involved in the dance …

We characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous
leukemia (CML) using a transgenic mouse model. LSC were restricted to cells with long …

The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid
leukaemia (CML) serves as a model for molecularly targeted therapy of cancer,,,, but at least …

The introduction of selective tyrosine-kinase inhibitors (TKIs) for the treatment of chronic
myeloid leukaemia has changed patient outcome and, consequently, management of this …